These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 27480537)

  • 41. MEDICAL DEVICE PRICES IN ECONOMIC EVALUATIONS.
    Akpinar I; Jacobs P; Husereau D
    Int J Technol Assess Health Care; 2015 Jan; 31(1-2):86-9. PubMed ID: 25989920
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Health technology assessment for medical devices in Europe. What must be considered.
    Siebert M; Clauss LC; Carlisle M; Casteels B; de Jong P; Kreuzer M; Sanghera S; Stokoe G; Trueman P; Lang AW;
    Int J Technol Assess Health Care; 2002; 18(3):733-40. PubMed ID: 12391964
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Key Recommendations from the MedtecHTA Project.
    Tarricone R; Torbica A; Drummond M;
    Health Econ; 2017 Feb; 26 Suppl 1():145-152. PubMed ID: 28139086
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intrinsic properties of medical devices: considerations for economic evaluation.
    Basu R; Eggington S
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):619-626. PubMed ID: 31721598
    [No Abstract]   [Full Text] [Related]  

  • 45. Estimating 'costs' for cost-effectiveness analysis.
    Miners A
    Pharmacoeconomics; 2008; 26(9):745-51. PubMed ID: 18767895
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The estimation of health state utility values in rare diseases: do the approaches in submissions for NICE technology appraisals reflect the existing literature? A scoping review.
    Meregaglia M; Nicod E; Drummond M
    Eur J Health Econ; 2023 Sep; 24(7):1151-1216. PubMed ID: 36335234
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Is the National Institute for Health and Care Excellence (NICE) in England more 'innovation-friendly' than the Federal Joint Committee (G-BA) in Germany?
    Schaefer R; Schlander M
    Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):453-462. PubMed ID: 30556745
    [No Abstract]   [Full Text] [Related]  

  • 48. A review of the economic tools for assessing new medical devices.
    Craig JA; Carr L; Hutton J; Glanville J; Iglesias CP; Sims AJ
    Appl Health Econ Health Policy; 2015 Feb; 13(1):15-27. PubMed ID: 25139635
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Use of economic evaluation in local health care decision-making in England: a qualitative investigation.
    Eddama O; Coast J
    Health Policy; 2009 Mar; 89(3):261-70. PubMed ID: 18657336
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Economic evaluation approaches for new technology.
    Papatheofanis FJ
    IEEE Eng Med Biol Mag; 2003; 22(3):16-7. PubMed ID: 12845811
    [No Abstract]   [Full Text] [Related]  

  • 51. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Health technology assessment of medical devices: What is different? An overview of three European projects.
    Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
    Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reallocating resources: how should the National Institute for Health and Clinical Excellence guide disinvestment efforts in the National Health Service?
    Pearson S; Littlejohns P
    J Health Serv Res Policy; 2007 Jul; 12(3):160-5. PubMed ID: 17716419
    [TBL] [Abstract][Full Text] [Related]  

  • 54. "Yes", "No" or "Yes, but"? Multinomial modelling of NICE decision-making.
    Dakin HA; Devlin NJ; Odeyemi IA
    Health Policy; 2006 Aug; 77(3):352-67. PubMed ID: 16213624
    [TBL] [Abstract][Full Text] [Related]  

  • 55. NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence.
    Bullement A; Taylor M; McMordie ST; Waters E; Hatswell AJ
    Pharmacoeconomics; 2019 Nov; 37(11):1383-1390. PubMed ID: 31250397
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research Needs.
    Rothery C; Claxton K; Palmer S; Epstein D; Tarricone R; Sculpher M
    Health Econ; 2017 Feb; 26 Suppl 1():109-123. PubMed ID: 28139090
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of NICE technology appraisal in NHS rationing.
    Walker S; Palmer S; Sculpher M
    Br Med Bull; 2007; 81-82():51-64. PubMed ID: 17409119
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion.
    Claxton K; Sculpher M; Culyer A; McCabe C; Briggs A; Akehurst R; Buxton M; Brazier J
    Health Econ; 2006 Jan; 15(1):1-4. PubMed ID: 16365910
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Integrating health economics modeling in the product development cycle of medical devices: a Bayesian approach.
    Vallejo-Torres L; Steuten LM; Buxton MJ; Girling AJ; Lilford RJ; Young T
    Int J Technol Assess Health Care; 2008; 24(4):459-64. PubMed ID: 18828941
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The South African Guidelines for Pharmacoeconomic Submissions' Evidence Requirements Compared with Other African Countries and The National Institute for Health and Care Excellence in England.
    Marsh SE; Truter I
    Expert Rev Pharmacoecon Outcomes Res; 2020 Apr; 20(2):155-168. PubMed ID: 31056961
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.